Esperion Therapeutics, Inc. (ESPR)
NASDAQ: ESPR · Real-Time Price · USD
1.500
-0.110 (-6.83%)
At close: Mar 28, 2025, 4:00 PM
1.501
+0.001 (0.05%)
After-hours: Mar 28, 2025, 7:59 PM EDT
Esperion Therapeutics Employees
Esperion Therapeutics had 304 employees as of December 31, 2024. The number of employees increased by 64 or 26.67% compared to the previous year.
Employees
304
Change (1Y)
64
Growth (1Y)
26.67%
Revenue / Employee
$1,093,138
Profits / Employee
-$170,214
Market Cap
296.77M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ESPR News
- 26 days ago - Esperion Therapeutics, Inc. (ESPR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 26 days ago - Esperion Reports Fourth Quarter and Full Year 2024 Financial Results - GlobeNewsWire
- 27 days ago - Esperion Partners with CSL Seqirus to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Australia - GlobeNewsWire
- 5 weeks ago - Esperion to Report Fourth Quarter and Full Year 2024 Financial Results on March 4 - GlobeNewsWire
- 6 weeks ago - Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 months ago - Esperion Strengthens Balance Sheet with Closing of Significant Refinancing Transactions - GlobeNewsWire
- 3 months ago - Undercovered Dozen: Ubiquiti, Ready Capital, Cardiff Oncology, Vodafone + - Seeking Alpha
- 3 months ago - Esperion Announces $210 Million Convertible Debt Financing - GlobeNewsWire